A new comprehensive parameter combining residual C-reactive protein and neutrophil risk predicting adverse events in Chinese patients after percutaneous coronary intervention - A multi-center prospective cohort study

Sep 29, 2026

Uploaded by nayy☆

Presents a prospective multi-center cohort study investigating a new comprehensive parameter that combines residual C-reactive protein with neutrophil-related risk to predict adverse events. The correspondence context highlights coronary heart disease in China and the role of residual inflammatory risk (RIR), with hsCRP indicating activation of inflammatory pathways such as NLRP3–IL-1β–IL-6. The study aims to validate combined predictive value of hsCRP and neutrophil-lymphocyte ratio (NLR) by categorizing RIR markers and assessing associations with MACCE in patients undergoing percutaneous coronary intervention.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Background

Residual inflammatory risk and hsCRP

Neutrophil-mediated inflammation and NLR

Study Objective

Joint prediction of hsCRP and NLR

Study Design

Prospective multi-center cohort

Clinical Context

Patients undergoing percutaneous coronary intervention

Correspondence A new comprehensive parameter combining residual C-reactive protein and neutrophil risk predicting adverse events in Chinese patients after percutaneous coronary intervention: A multi-center prospective cohort study Fen Yang1,2,3,4, Miao Yu1,2,3,4, Yuanfan Yuan1,2,3,4, Jiahao Xu1,2,3,4, Meilin Liu1,2,3,4, Shaofang Nie1,2,3,4, Yuyan Xiong1,2,3,4, Liuyu Yu1,2,3,4, Qi Long1,2,3,4, Zhengfeng Zhu1,2,3,4, Lingfeng Zha1,2,3,4, Jinying Zhang5, Qiang Xie6, Xuebin Han7, Xiaolan Li8, Jian Yang9, Keping Yang10, Liqun He11, Manhua Chen12, Liqun Hu13, Lifeng Hong14, Kefei Dou15, Yuhua Lei16, Wei Yao17, Zhilei Shan18, Peter Libby19, Xiaozeng Wang20, Yaling Han20, Haitao Yuan21, Xiang Cheng1,2,3,4 1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; 2Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; 3Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; 4Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei 430022, China; 5Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China; 6Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361026, China; 7Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi 030024, China; 8Department of Cardiology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, China; 9Department of Cardiology, The First College of Clinical Medical Science, Three Gorges University and Yichang Central People’s Hospital, Yichang, Hubei 443000, China; 10Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, China; 11Department of Cardiology, Wuhan No. 1 Hospital, Wuhan, Hubei 430031, China; 12Department of Cardiology, Central Hospital of Wuhan, Wuhan, Hubei 430021, China; 13Department of Cardiology, Wuhan Fourth Hospital, Wuhan, Hubei 430000, China; 14Department of Cardiology, The Fifth Hospital of Wuhan & Cardiovascular Institute of Jianghan University, Wuhan, Hubei 430000, China; 15Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China; 16Department of Cardiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, China; 17Department of Cardiology, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei 441300, China; 18Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; 19Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA; 20Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110017, China; 21Department of Cardiology, Shandong Provincial Hospital, Jinan, Shandong 250021, China. To the Editor: Coronary heart disease (CHD) continues tobe a predominant cause of mortality in China even after recommended optimal management. [1] Residual inflammatory risk (RIR) portends increased risk of recurrent cardiovascular events. As an indicator of pro-inflammatory nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3)–interleukin (IL)-1β–IL-6 pathway activation, high-sensitivity C-reactive protein (hsCRP) has demonstrated significant value as a predictor of major adverse cardiovascular and cerebrovascular events (MACCEs) . [2] Due to the ethnic

FAQs

What inflammatory indicators are used in the proposed comprehensive parameter?

The parameter combines residual C-reactive protein with neutrophil-related risk, including neutrophil-lymphocyte ratio (NLR) as part of the RIR framework.

What clinical population does the study focus on?

Patients undergoing percutaneous coronary intervention (PCI) in Chinese cohorts are assessed for adverse cardiovascular outcomes.

How are adverse events evaluated in relation to RIR markers?

The study examines associations between different residual inflammatory risk (RIR) categories—derived from combined hsCRP and NLR markers—and major adverse cardiovascular and cerebrovascular events (MACCE).

Sep 29, 2026

Uploaded by nayy☆